Basic Information
OncoMyx Therapeutics Develops Oncolytic Immunotherapies Based on the Myxoma Virus (MYXV) Platform to Coordinate Immune Responses and Treat Cancer. The Company’s MYXV Platform Is Expected to Become a First-in-Class OV Approach.
OncoMyx Therapeutics, Inc.
Tucson,Arizona,United States of America
less than 15 people
January 01, 2018
hr@oncomyx.com